Cat. No. | Product name | CAS No. |
DC10593 |
CPI-455 analogue(KDM5 inhibitor)
Featured
CPI-455 analogue is a selective inhibitor of KDM5 demethylases. |
|
DC9858 |
CPI-455
Featured
CPI-455 is a specific, pan-KDM5 inhibitor with an IC50 of 10 nM for KDM5A. CPI-455 mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents. |
1628208-23-0 |
DC10591 |
CPI-613
Featured
CPI-613 is an E1α pyruvate dehydrogenase (PDH) modulator that prevents cancer cells from metabolizing glucose for energy. CPI-613 has been granted orphan drug status by the US FDA for pancreatic cancer. |
95809-78-2 |
DC10477 |
CPI-637
Featured
CPI-637 is a potent and selective CBP/EP300 bromodomains inhibitor with IC50 of 0.03±0.01μM and 11.0±0.6 μM for CBP/EP300 and BRD4, respectively. |
1884712-47-3 |
DC9508 |
CPPHA
Featured
CPPHA is a selective positive allosteric modulator of mGluR5 receptor. |
693288-97-0 |
DC23765 |
CPYPP
Featured
CPYPP is a small-molecule inhibitor of the Rac activator DOCK2 with IC50 of 22.8 uM (DOCK2DHR-2-mediated Rac GEF activity), inhibits DOCK2-Rac1 interaction. |
310460-39-0 |
DC12396 |
CR4056
Featured
CR4056 (CR 4056, CR-4056) is a novel, orally active imidazoline-2 receptor (I2R) ligand with binding IC50 of 596 nM, also selectively inhibits the enzymatic activity of MAO-A with IC50 of 202.7 nM; increases norepinephrine (NE) tissue levels both in the rat cerebral cortex and lumbar spinal cord, shows ED50 of 5.8 mg/kg in CFA rat model of inflammatory pain; shows high effectivity against bortezomib-induced painful neuropathy in rats. |
1004997-71-0 |
DC11380 |
Difelikefalin (CR845)
Featured
Difelikefalin (CR-845; FE-202845) is a peripherally restricted and selective agonist of kappa opioid receptor (KOR). Difelikefalin produces anti-inflammatory effects and has the potential in modulating pruritus in conditions such as chronic kidney disease[1][2]. |
1024828-77-0 |
DC20347 |
Crebinostat
Featured
Crebinostat is a novel cognitive enhancer that inhibits class I HDAC/1/2/3 (IC50=0.7/1.0/2.0 nM), class IIb HDAC6 (IC50=9.3 nM) with weaker inhibition of the class I HDAC8 and no significant inhibition of the class IIa HDAC/4/5/7/9; potently induces acetylation of both histone H3 and histone H4 as well as enhanced the expression of the CREB target gene Egr1 in cultured mouse primary neurons; upregulates Bdnf and Grn, and downregulates Mapt (tau) gene expression-genes; brain penetrant. |
1092061-61-4 |
DC5159 |
CP-868596 (Crenolanib)
Featured
Crenolanib (CP-868596) is a potent and selective inhibitor of PDGFRα/β with Kd of 2.1 nM/3.2 nM, also potently inhibits FLT3, sensitive to D842V mutation not V561D mutation, >100-fold more selective for PDGFR than c-Kit, VEGFR-2, TIE-2, FGFR-2, EGFR, erbB |
670220-88-9 |
DC11642 |
Cridanimod sodium
Featured
Cridanimod sodium is a potent type I interferon (IFN) inducer that directly binds to STING and triggers a strong antiviral response through the TBK1/IRF3 route. |
58880-43-6 |
DC22634 |
Crizotinib hydrochloride
Featured
Crizotinib (PF-02341066;PF-2341066) is a potent, selective, orally bioavailable, ATP-competitive inhibitor of c-Met catalytic activity with Ki of 4 nM. |
1415560-69-8 |
DC20999 |
CS-3150 (Esaxerenone;XL-550)
Featured
CS-3150 (Esaxerenone, XL-550) is a highly potent, selective and orally active non-steroidal mineralocorticoid receptor antagonist with IC50 of 9.4 nM; displays >1,000-fold selectivity over other steroid hormone receptors, glucocorticoid receptor, androgen receptor and progesterone receptor; inhibits aldosterone-induced transcriptional activation of human mineralocorticoid receptor with IC50 of 3.7 nM, shows superior potency to that of spironolactone and eplerenone; suppresses aldosterone-induced decrease in urinary Na(+)/K(+) ratio, inhibits blood pressure elevation induced by DOCA/salt-loading in rats. |
1632006-28-0 |
DC20089 |
CSF1R-IN-1
Featured
CSF1R-IN-22 is a potent, cellular active and orally bioavailable CSF1R inhibitor with IC50 of 0.5 nM, displays 120-fold selectivity over c-Kit; has improved metabolic stability and Caco2 permeability. |
2095849-04-8 |
DC22209 |
CSLP37
Featured
CSLP37 (RIPK2 inhibitor CSLP37) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 16.3 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling. |
2244984-64-1 |
DC12576 |
CSRM617
Featured
CSRM617 (CSRM-617) is a small-molecule inhibitor of the transcription factor ONECUT2 (OC2) with Kd of 7.43 uM in SPR assays, binds to OC2-HOX domain directly. |
787504-88-5 |
DC12661 |
CT1812
Featured
CT 1812 is a proprietary first-in-class, orally available sigma-2/PGRMC1 antagonist (alpha beta oligomer receptor antagonist |
1802632-22-9 |
DC7110 |
CTEP
Featured
CTEP is a novel, long-acting, orally bioavailable allosteric antagonist of mGlu5 receptor with IC50 of 2.2 nM. |
871362-31-1 |
DC11217 |
SLC25A1 inhibitor CTPI-2
Featured
CTPI-2 (SLC25A1 inhibitor CTPI-2) is a novel specific SLC25A1 inhibitor with Kd of 3.5 uM, CTPI-2 is synthetic lethal with cisplatin or with EGFR inhibitor co-treatment and restores antitumor responses both in vitro and in vivo; disrupts self-renewal and |
68003-38-3 |
DC7904 |
CTX0294885
Featured
CTX-0294885 is a novel broad-spectrum kinase inhibitor. |
1439934-41-4 |
DC10771 |
CU-CPT-8m
Featured
CU-CPT-8m is a nolve TLR8 inhibitor. |
125079-83-6 |
DC10769 |
CU-CPT-9b
Featured
CU-CPT9b is an antagonist of toll-like receptor 8 (TLR8; Kd = 21 nM). |
2162962-69-6 |